Annals of Oncology Advance Access originally published online on November 16, 2007
Annals of Oncology 2008 19(3):577-582; doi:10.1093/annonc/mdm508
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
oncology practice |
Management of bevacizumab-associated bowel perforation: a case series and review of the literature
1 Department of Surgical Oncology
2 Department of Medical Oncology
3 Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
* Correspondence to: Dr J. N. Cormier, Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Tel: +1-713-792-6949; Fax: +1-713-745-1921; E-mail: jcormier{at}mdanderson.org
Background: This study examined the various approaches to the management of perforation and the associated outcomes in patients with bevacizumab-associated bowel perforation at a tertiary cancer center.
Patients and methods: Our institutional pharmacy database was searched to identify all patients who had received bevacizumab over a 2-year period (January 2004 to October 2006). Medical records of these patients were examined for reports of confirmed bowel perforation or fistula, associated clinicopathological factors, treatment, and outcomes.
Results: We identified 1442 patients who had been treated with bevacizumab over the study period with perforation occurring in 24 (1.7%). The breakdown of these 24 patients by disease site was as follows: ovarian (3 of 50, 6%), gastroesophageal (2 of 38, 5.3%), pancreatic (7 of 141, 5%), unknown primary (1 of 60, 1.7%), lung (1 of 67, 1.5%), colorectal (6 of 478, 1.3%), and renal cell (4 of 269, 1.5%). The majority of patients (n = 19, 79%) were initially managed nonoperatively. Only five (21%) patients ultimately underwent surgical exploration, with a subsequent anastomotic leak developing in one patient. The overall 30-day mortality rate was 12.5%.
Conclusions: Bevacizumab-associated bowel perforation occurs in patients with various malignancies, with an incidence of 1.7%. Nonoperative treatment is a viable approach to management in selected patients.
Key words: avastin, bevacizumab, complication, GI perforation, toxicity
Received for publication July 27, 2007. Revision received September 26, 2007. Accepted for publication October 1, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. S. Shord, L. R. Bressler, L. A. Tierney, S. Cuellar, and A. George Understanding and managing the possible adverse effects associated with bevacizumab Am. J. Health Syst. Pharm., June 1, 2009; 66(11): 999 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Norden, J. Drappatz, A. S. Ciampa, L. Doherty, D. C. LaFrankie, S. Kesari, and P. Y. Wen Colon perforation during antiangiogenic therapy for malignant glioma Neuro-oncol, January 1, 2009; 11(1): 92 - 95. [Abstract] [Full Text] [PDF]
|
|